Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialize zilganersen for the treatment of Alexander disease (AxD) in countries outside the United States. This strategic partnership marks a significant step in the advancement of therapies for rare neurological conditions, particularly as AxD currently lacks approved treatment options.
The collaboration not only underscores Ionis’s commitment to expanding the reach of its innovative therapies but also positions Recordati to leverage its expertise in rare diseases within the global market. By transferring these rights, Ionis can focus on its core pipeline while enabling Recordati to navigate regulatory pathways and market dynamics in various international jurisdictions.
This agreement has implications for both companies, as it allows Ionis to potentially receive milestone payments and royalties, while Recordati gains access to a promising asset that could enhance its portfolio in the rare disease space. The successful development of zilganersen could pave the way for new treatment paradigms in AxD, reflecting the growing interest in addressing unmet medical needs in niche therapeutic areas.
Use the database as your supply chain compass →
